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Biophamaceuticals promise a wide variety of benefits to modern medicine. The ability to 
produce highly effective, low-cost treatments for genetic diseases and other illnesses places a 
high degree of importance on biopharmaceutical techniques. Acting in concert or as an 
analogous replacement, biopharmaceutical proteins are a bold, promising technology poised to 
have major impacts on human health. Glycoproteins are a particularly well-researched 
biotherapeutics class that display high specificity and efficacy in treating numerous diseases. 
Bulk production of protein therapeutics requires careful monitoring of many factors. Cell type, 
media quantification, and glycosylation patterning are all relevant points of analysis. 
Glycosylation in particular, how sugar structures are assembled on amino acid residues, is an 
extremely important regulatory mechanism. Chinese hamster ovary cells are often used in order 
to provide a viable production platform with human-similar glycosylation.  
Within glycosylation, it has been found that terminal sialic acid (N-acetylneuraminic acid, 
NeuAc, NeuGc) content on the glycan correlates with many positive in vivo effects, including 
increased half-life, reduced clearance, and more direct site recognition. Because of the 
importance of terminal sialic acid, many techniques exploit differing aspects of cell biology in 
order to increase the volume of terminal sialic acid. We study the effects of chemical biology and 
the utilization of analogs of ManNAc, a sialic acid precursor commonly used to increase 
available cellular sialic acid as a biochemical approach to promote sialic acid availability.  
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Chapter 1: Introduction 
Biopharmaceuticals, drugs of origin from a living organism, showed $100 billion in 2010 
earnings, a trend which shows no inclination towards slowing down. [47] Broadly, 
biopharmaceuticals consist of the classes of proteins, hormones, and other complex 
macromolecules that are difficult to synthesize without the specialized biological equipment 
inherent in living cells. [16, 19] 
In contrast to traditional, lab-synthesized chemical pharmaceuticals, biopharmaceutical 
provide several useful advantages, which include known activity, controlled side effects, cost 
effectiveness, as well as high specificity and effectiveness. [40] Drugs such as Remicade and 
Rituxan provide relief in ways that dramatically improve the quality of life in their recipients. 
[39, 53, 58] In fact, many engineered proteins are designed to improve upon native traits inherent 
to their standard function. “Biosuperiors,” are hoped to act in place of their original incarnation, 
and achieve even better results. [33, 38]  
These benefits are not without drawbacks. Biopharmaceuticals are often cleared very 
quickly from serum, and can suffer from low activity. [21, 24] However, a common feature these 
drugs share lies in their post-translational modification. Over two-thirds of biopharmaceutical 
proteins are heavily glycosylated. Glycosylation refers to sugar structures built up from protein 
residues, and the uniqueness of these outer shells are responsible for many aspects of solubility, 
activity, serum half-life, and structural stability. [12, 18] 
In order to conserve the glycan structures and thereby valued aspects of the produced 
proteins, it is important to utilize a platform which can produce the protein with high fidelity, 
volume, and speed. Due to the importance of a protein’s glycosylation, a common optimization 
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goal in biopharmaceutical production is the act of “humanizing” a protein by modifying labeling 
structures called glycans. [21, 63] 
Chinese hamster ovary cells are a valued platform used to produce upwards of 80% of 
on-market human protein therapeutics. The reasons for the use of these particular cells, opposed 
to humans, are due to their low maintenance, efficient growth rate, and highly conserved 
mechanisms that produce human-like glycosylation patterns. [7, 52, 54] 
1.1 Cell Culture 
In order to produce a broad volume of a desired therapeutic, it is important to utilize a 
platform which expresses human-mimetic proteins, and produces them at a high rate. Cell culture 
has proven to be a reliable way to produce bulk scale proteins. [61] 
Broadly, cell culture refers to the process of growing cells within a liquid medium, rather 
than harvesting them from a treated animal. The medium is then supplemented with nutritional 
items or other tools used to parameterize various aspects of cellular metabolism or protein 
throughput. [1, 42] Cells in the liquid medium are then maintained under a variety of conditions 
of agitation, temperature, O2 and CO2 feeds. [50] Mammalian cells are typically grown in media 
supplemented with essential amino acids which cannot be synthesized by the cells, as well as 
numerous buffers and drugs. [40, 44] 
 Chinese hamster ovary (CHO) is a commonly used platform for expressing human 
proteins. This is due to multiple factors. The primary factor is low maintenance. CHO are robust 
and can be used for multiple conditional examinations. [2, 10] A second is the relatively low 
complexity of the CHO genome, allowing for clarity of genetic analysis and well-documented 
3 
 
knowledge regarding gene inserts and substitutions commonly used in genetic engineering for 
protein expression. [33] 
 Of interest to this work is the similarity of glycosylation machinery conserved between 
human subjects and CHO. [4] 
1.2 Glycosylation 
1.2.1 Glycosylation Overview 
Glycans arise as a result of post-translational modification in the golgi apparatus in a 
process known as glycosylation. Many important protein characteristics arise by covalently 
attaching sugar residues in glycosidic linkages extending from an amino acid residue. [11] 
Glycosylation can broadly be described in two forms, contingent on the linkage between the 
protein’s core structure and the initializing carbohydrate. N-glycosylation arises on sites with a 
residue sequence of Asn-X-Ser/Thr, where X can be any non-proline amino acid. [6] By contrast, 
O-glycosylation occurs when the initial sugar attaches to an oxygen present on a serine or 
threonine residue. [26] 
Glycosylation regulates many important factors of a fully complete glycoprotein, 
including solubility, resistance to degradation, immune response, cellular signaling, adhesion, as 
well as protein/protein interactions and the proper structure of a protein itself. [4, 10] Many of 
these important characteristics are particularly controlled by the terminal (most distant from the 
protein) sugars on the glycan structure. Sialic acid (N-acetylneuraminic acid) is of particular 
note, and is the only functional carbohydrate with a negative charge. [5, 6] Sialylation refers to 
the addition of sialic acid to a forming glycan, and is of particular interest to bioengineers, and 
will be addressed in detail in further sections.  
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Although glycoproteins can vary considerably both in their protein structure as well as 
the final form of their completed glycans, all glycans share a common “core” structure of 
carbohydrate moieties. In particular, N-acetylglucosamine and mannose (GlcNAc and Man, 
respectively) consist of a vital set of linkages upon which variants in glycans form. Glycan labels 
are described by listing the sugar in question, and the order of carbons on the central ring 
structure that are interlinked. For example, the preserved core structure shows the following 
series of bonds and moieties: Man(α)1,3(Manα1,6) Manβ-1,4GlcNAc β-1,4GlcNAc-Asn. The 
descriptor Man(α)1,3(Manα1,6) refers to the linkages of the initial mannose’s first carbon to the 
three carbon on the second mannose, as shown below in Figure 1. [11, 20] 
From this core structure, regulation via additional processing and severed residues 
diversify glycan structures within the Golgi apparatus to the wide variety of shapes which can be 
used to characterize glycoproteins. 
1.2.2 Glycan Variation 
Glycan structures are characterized into complex, high mannose, and hybrid types. A 
schematic representation is shown of these types, as well as the core structure, below in Figure 1.  
 
Figure 1 Common glycoforms. The high mannose type displays a preponderance of mannose, complex by contrast shows a 
wider variation of sugars. The hybrid type is mixed, and shows a mannose branch as well as an alternating, complex branch. 




Table 1 Schematic representation of common sugars in glycan forms. While some sequences in glycans are relatively 
predictable, the table displays common sugars and their linkages within glycans. [65] 
Between two and six connected mannose residues comprise high mannose glycans 
extending from the core structure. Hybrid type continues this overall trend, by displaying a 
characteristic GlcNAc β1,4 linkage to a β1,4 mannose in the pentasaccharide core. [60] 
By contrast, complex types include a galactose (Gal) β1,4 bond to a β1,2-GlcNAc, and 
end in a terminal sialic acid (Sia) group. Structures of this type and this terminal group are 




Figure 2 N-acetyl neuraminic acid. The most commonly occurring sialic acid (in addition to Neu5Ac and Neu5Gc, among 
others), N-acetyl neuraminic acid is responsible for many important biotherapeutics effects. [59] 
1.2.3 Sialyation and Sialic Acid  
Sialyation is the process by which a sialic acid is linked to a terminal galactose on a 
glycoprotein’s glycan. Sialic acids consist of a broad family of related, negatively charged, nine 
carbon polyhydroxylate α-keto acids, the most common of which is NeuNAc, N-
acetylneuraminic acid. Sialyation correlates strongly to several very important effects on proteins 
of interest: increased serum halflife, immune evasion, and proper secretion of many valuable 
biopharmaceutical products of interest, such as erythropoietin (EPO). [56, 58] 
Although sialic acid as a class promotes these positive benefits as the terminal glycan, 
other important things to note are that NeuNAc is not the only sialic acid incorporated into 
human terminal groups. Many cellular processes regulate terminal sugars, and these alternates 





Figure 3 Sialic Acid Pathway. UDP-GlcNAc, ManNAc, et al are shuttled through various enzymatic processes in order to 
finally transform the molecules into CMP-Neu5Ac or other such SA variants, before finally being assigned to a glycan within the 
Golgi. [12] 
An important factor in glycan formation is a cell’s available pool of sialic acid. NeuNAc 
generation can occur from a wide variety of precursor molecules, such as ManNAc, UDP-
GlcNAc, and other precursors. [6, 64] Evidence has shown that a cell’s pool of a given terminal 
sugar correlates strongly to the degree by which that terminal sugar is displayed. [61, 64] 
Therefore, a viable engineering and optimization avenue is to increase the volume of available 
cytosolic sialic acid, and its precursors, which in turn can be translated into SA. [53, 55] Many 
avenues have been described to approach this end, including upregulating enzymes responsible 
for precursor turnover, resulting in increased flux through the pathway, and other efforts to 
humanize biotechnology platforms to create more human-mimetic sialic acid patterns. [42, 43, 
56] 
  In addition to sialic acid, the patterns of branching which describe human proteins are 
highly specific. Not only is the actual sialic acid itself important, but the pattern as well. 
Engineering enzymes either to upregulate the host’s throughput to desired varieties of SA, or to 
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mimic non-native human patterns, has proven to be a challenging, if rewarding, method of 
improvement. [28, 30, 37] 
 
Figure 4 Branching patterns of glycosyltransferase class enzymes (GnT). As shown, the ability of a glycan to split into its 
branched linkages is contingent largely on the GnTs present in the platform. While these enzymes are native to most human cells, 
CHO are missing α2,6-driving GnT. [12, 33] 
  However, genetic engineering yields several drawbacks. The effort necessary to create a 
cell line with improved glycosylation mechanisms is substantial, often involving expensive 
reagents, in conjunction with long-term studies to confirm the stable incorporation of the gene 
into the cell line. [38, 48] Additionally, when it becomes necessary to repeatedly engineer 
enzymes related to glycosylation pathways, given an enzyme’s highly specific function, the 
necessary time and monetary input increases substantially. [3, 12, 25] 
  One effective, broad-scale alternative to increase sialic acid content is through chemical 




Chapter Two: ManNAc Analogs 
2.1 N-Acetyl Mannosamine monohydrate (ManNAc) 
While increasing cellularly available SA can be accomplished through many means, the 
direct addition of SA is inarguably the simplest in concept. In practice, mere addition of SA 
requires more finesse than simply adding it to a culture’s media. Sialic acids as a group are 
ineffective at crossing the cell membrane. [3, 9, 25] However, the same is not true of their 
numerous precursors, such as ManNAc (N-acetyl Mannosamine monohydrate). As described 
above, ManNAc feeds into the SA synthesis pathway via the enzyme GNE, which converts 
ManNAc to ManNAc-6-Phosphate, which is in turn converted to NeuNAc-9-P by NANS, after 
which it follows the diagram described in Figure 3. [65] 
 
Figure 5 N-acetylmannosamine. ManNAc is a key precursor to sialic acid, and is a useful tool in increasing readily available 
SA content in a culture’s cytoplasmic space. It is important because it, unlike the desired SA, is capable of crossing the plasma 
membrane and penetrating the cell. [37] 
 Like all chemical compounds, engineers have sought to improve upon ManNAc in the 
form of ManNAc analogs, which take the core ManNAc structure and augment them with 




Figure 6 Derived ManNAc analogs. As shown, a wide variety of chemical modifications to the core ring structure as well as 
side groups is possible for ManNAc. These molecules are all similar enough to “standard” ManNAc that they are uptaken into the 
SA metabolic pathway, though they yield different effects when installed as terminal glycans. [2] 
2.2 ManNAc Analogs 
  There exist a wide variety of synthesized ManNAc analogs, all of which show varied 
levels of effectiveness in increasing protein SA content, promoting cell survivability, or other 
utility such as available azide groups for labeling or separation purposes. A variety of these 
analogs are displayed in Figure 6.  
 
Figure 7 Simple ManNAc Pathway. ManNAc is capable of undergoing isomeric shifts, but the addition of pyruvate drives it 




Figure 8 Sialic acid pathway versatility. The SA pathway is relatively non-specific provided the feed molecules follow certain 
constraints. As demonstrated above, many ring variants as well as side groups are all incorporated into the glycan. [54] 
2.2.1 Ac4ManNAc 
Ac4ManNAc has seen use in cultures in attempts to sialic acid content on glycoproteins 
of interest. Prior work shows that the Ac4 analog accomplishes this well, but at a cost. [3] Ac4 
has been shown to have numerous cytotoxic effects, and its low dosing requirements correspond 
to a minimal effectiveness in the increase in SA content. Relative to ManNAc, it is a viable 
alternative particularly in that it can be synthesized without a great deal of additional difficulty 
and can be used at far lower volumes to achieve corresponding benefits. [24, 25] 
2.2.2 Butyrated Analogs  
Butyrate is commonly used to functionalize membrane penetrants. As a hydrophobic 
group, it easily crosses the cell membrane. Compared to the acetyl group, which is often 
associated with poisonous metabolic products, butyrate’s toxicity threshold tends to be much 
higher. For these reasons, we examined the utility of Bu groups as additions to the ManNAc 
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analogs and whether or not they would be able to provide useful function over Ac4ManNAc. [51]
 In this study, we examined the ability of Ac4 and two proposed competitor molecules: 
1,3,4-O-Bu3ManNAc and Bu4ManNAc.  
 
Figure 9 1,3,4-O-Bu3ManNAc. The molecule of interest in this work. Not the positions and modifications from standard 
ManNAc of the Bu groups at the 1, 3, and 4 carbons. [2] 
2.3 Materials and Methods 
2.3.1 Cell Culture and Treatment 
  Adherent CHO-K1 cells (Sigma-Aldrich, St. Louis, MO) were cultured in variable well 
plates utilizing a staged sequence of one day growth under F-12K Medium (Life Technologies, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Thermo Scientific, Waltham, 
MA) for one day in order to promote initial cellular growth and plate adherence. Cells were 
grown in conditions of 5% CO2 and 37Co for 24 hours in a Series 8000 Direct Heat and Water 
Jacket CO2 incubator (Thermo Scientific, Waltham, MA). After this initial growth period, media 
was removed and cells were washed with Dulbecco’s phosphate buffered saline (PBS) (Life 
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Technologies, Carlsbad, CA), which was then aspirated off. Cells were then fed a uniform 
volume of OptiMEM Serum-Free media mixed with varied concentrations of ManNAc, 1,3,4-O-
Bu3ManNAc, Bu4ManNAc, Ac4ManNAc variants. ManNAc and analogs used were solubilized 
in ethanol or a water/ethanol mix. The volume of ethanol used to solubilize and mix the 
chemicals into the media was found to constitute at maximum .04% of the media volume for the 
highest concentration (.68µM). [55, 66] Per previous investigation, this concentration shows 
minimal effect on culture viability until an ethanol composition of media reaches 1mM over 24 
hours. [55, 66]  These analogs and base ManNAc were generously provided by the Kevin 
Yarema lab, Department of Biomedical Engineering, Johns Hopkins University. In total, each 
concentration condition per set was tested in triplicate per set, three for growth and three for 
lysate collection. Each condition was tested this way a minimum of three times, with conditions 
of interest repeated upto eight.  
2.3.2 Collection  
  After a further 24 hour period after the secondary incubation period, a selection cultures 
had media and cell waste aspirated off, and were then washed with PBS. One volume of cells 
was removed from the plate using .25% -Trypsin EDTA (Life Technologies, Carlsbad, CA), and 
a second volume of identical treatment was lysed directly by the addition of RIPA buffer and 
consolidated via a rubber policeman. Each sample was separately moved to a 1ml centrifuge tube 
(Sigma-Aldrich, St. Louis, MO) and labeled.  
  The whole cell lysate samples were then sonicated at 20 amps for a pulse of five seconds 
to disrupt remaining cell debris. The samples were then centrifuged at 10,000 RPM in a  
centrifuge for 10 minutes. (Eppendorf, Hamburg, Germany).The supernatant, containing the 
protein samples, was then collected for further analysis.  
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2.3.3 Cell Density Counts 
  Living cell counts were determined via a Tryphan blue (Sigma-Aldrich, St. Louis, MO) 
assay at a 1:1 dilution using a hemocytometer (Thermo Fisher, Waltham, MA). Counts per 
sample were done in triplicate, per individual well sampled. These values were then scaled up to 








= 𝐴𝑝𝑝𝑟𝑜𝑥 𝐶𝑒𝑙𝑙𝑠/𝑀𝑙 
 Due to the large volume necessary to glean data from the broad number of parameters 
tested, wells of varied size were utilized to conduct multiple studies in parallel. In order to have a 
uniform distribution (due to variable available grow space and the necessity of media volume), 
cell counts were then scaled to a per mm2 basis for density.  
2.3.4 Enzyme Linked Immunosorbent Assay (ELISA) 
  A BCA assay  (Thermo Scientific, Waltham, MA). was performed on whole cell lysate 
samples to determine total protein volume collected from the cell lysate and evaluated using a 
spectrophotometer at the 562nm wavelength (BIO-RAD, Hercules, CA; Sigma-Aldrich, St. 
Lous, MO). These values were compared to uniform standards on a 96-well basis, allowing for 
the testing of 38 duplicates per plate. Individual assay equations were tabulated in order to 
establish standard deviation within the protein volumes collected. Protein volumes collected 
were used to determine concentrations within the volume of lysate remaining, which was then 
diluted to a standard value equivalent to the lowest concentration found. For instance, with two 
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protein samples of 30µg/µl and 10µg/µl, to have parity, both samples would need to be fed at 
10µg/µl into the electrophoretic analysis.  
2.3.5 SDS-Page 
  After uniform scaling per the BCA assay evaluation, samples were stained in 1x Laemelli 
blue buffer with β-mercaptoethanol (BIO-RAD, Hercules, CA; Sigma-Aldrich, St. Lous, MO) 
and denatured by boiling at 90Co for 5 minutes.  
  Samples of interest were loaded into 10% polyacrylamide gels with uniform 
concentration, as evaluated per the Pierce ® BCA protein assay kit (Thermo Scientific, Waltham, 
MA). Equal volumes at the selected concentration were loaded into the gel, with each position 
carefully monitored upon initial loading relative to the ladder.  
  Denatured samples were separated by running at 120V for 80 minutes at room 
temperature. Protein was then transferred from the gel to an Immuno-Blot ® 
polyvinylidenedifluoride (PVDF) membrane (BIO-RAD, Hercules, CA) at 200V for 75 minutes 
at room temperature under mild agitation.  
2.3.6 Western/Lectin Blot 
  A western blot was performed using lectins as the primary and secondary antibody to 
evaluate the content of terminal sialic acid in the whole cell lysate. Lectins are proteins which 
bind to specific sugars, rather than conjugate sites per standard antibodies used in the evaluation 
of specific protein content. Using the PVDF membrane developed by the SDS-PAGE method, it 
was then incubated in 5% milk dissolved in PBST (phosphate buffered saline , with with 0.1% 
Tween-20 (Life Technologies, Carlsbad, CA; Sigma-Aldrich, St. Louis, MO) added) for 60 
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minutes. Following preblocking, the membrane was treated with PBST containing a 1:500 
dilution of biotinylated Ig-like Lectin I (Life Technologies, Carlsbad, CA), as a primary antibody 
to sialic acid. After incubation for 2 hours, the membrane was washed for 5 minutes in PBST 3 
times. The 15 minute wash period was followed by a treatment in 5ml of 1:2000 dilution of 
streptavidin (Life Technologies, Carlsbad, CA), in PBST. The study was terminated with three 
further 5 minute PBST washes.  
  The lectin blots were resolved using a Western Blot Chemiluminescence SuperSignal  
(Life Technologies, Carlsbad, CA) detection kit to visualize light response to biotinylation, a 1:1 
mixture of reagents in the kit were used to develop the blots.  
2.4 Results 
2.4.1 Effect of Analogs on Cell Growth  
2.4.1.a Operating Frame and Concentration Ranges 
  Figure 10 shows initial studies into growth rates over the course of one week using 
various concentrations of Ac4ManNAc and 1,3,4-O-Bu3ManNAc. As the compounds of interest, 
these were used to generate a kill curve and operating range of concentrations for each 
compound. In the case of both compounds, higher concentrations have shown a dramatic 
decrease in cellular growth over time. The Ac4ManNAc variant is known to be used primarily 




Figure 10 Kill Curve. 1,3,4-O-Bu3ManNAc and Ac4ManNAc were tested in parallel to examine the relative toxicity and 
determine an optimal range of cell function and treatment. As shown, the 1000µM concentration-treated cells fared the worst, 
with diminishing negative effects on cell growth as the concentration decreases. Additionally, Bu3 appears to be overall less 
toxic, as the 1000µM concentration still outgrows all but the two lowest (10 and 50µM) Ac4 treatments. 
  By contrast, 1,3,4-O-Bu3ManNAc showed negative effects on growth, but these effects 
were dramatically attenuated compared to the sister Ac4 compound. In fact, when the results 
were normalized (Figure 11), cells under 1,3,4-O-Bu3ManNAc treatment outgrew the Ac4-
treated cells by an appreciable margin. After the initial kill curve assay, it was determined that 
based on Ac4’s established industrial ranges and an observable shift from lag phase into 
exponential phase within some of the treatments and WT at day 5, as compared to a significant 
decrease in growth or even death, that five days of observation would prove to be a useful range 
to observe and reproduce results. 
  To adequately compare competition at uniform concentrations, treatments were 
performed at the same concentration to determine that concentration’s effect on growth, protein 





































Figure 11 Averaged Kill Curve. This takes the data from above and averages the growth for Ac4ManNAc and 1,3,4-O-
Bu3ManNAc treatments, forming a roughly linear curve over the days. While WT reaches an exponential phase, the relative 
weighting of the low yield of cell mass higher concentrations lower the total cell volume for the aggregate, giving the shape 
presented. The important thing to note is that even when averaging across concentration (which are fed at identical µM between 
the two chemicals), Bu3 yields a higher total number of cells across the samples tested.  
2.4.1.b Growth Conditions  
  While the cells were treated uniformly for environmental conditions, different 
concentrations of the various chemicals used displayed profound effects on culture growth, 
particularly as the length of the experiment continued. Figures 12, 13, and 14 show the collected 
average of cell volume for days 1, 3, and 5 respectively. It is important to note that each figure is 
the aggregate of multiple data points sampled within a uniform time frame rather than a bulk 
collection of data. Due to the volume of labor necessary to obtain these results, it would be 
prohibitive to gather the entirety of this data during the course of a single week. 
  For example, one experiment consisted of treatments 1-11, (or other such combinations) 
which were sampled in triplicate at 24 hours after initial feeding, 72 hours after initial feeding, 



























consisted of treatments 1, 3, 12, 13, and 14 (or other such combinations). The volume of data 
collected per treatment type is factored in to the standard deviations displayed in the figures, and 
efforts were put forth to describe each treatment with a large volume of samples irrespective of 
the relative importance of those samples.   
Chemical  Concentration Label 
None  Null 1 
ManNAc 100µM 2 
ManNAc 250µM 3 
ManNAc 1000µM 4 
Bu4ManNAc 50µM 5 
Bu4ManNAc 250µM 6 
Bu4ManNAc 500µM 7 
Ac4ManNAc 50µM 8 
Ac4ManNAc 100µM 9 
Ac4ManNAc 250µM 10 
Ac4ManNAc 500µM 11 
1,3,4-O-Bu3ManNAc 20µM 12 
1,3,4-O-Bu3ManNAc 30µM 13 
1,3,4-O-Bu3ManNAc 50µM 14 
1,3,4-O-Bu3ManNAc 75µM 15 
1,3,4-O-Bu3ManNAc 100µM 16 
1,3,4-O-Bu3ManNAc 125µM 17 
1,3,4-O-Bu3ManNAc 150µM 18 
1,3,4-O-Bu3ManNAc 250µM 19 
1,3,4-O-Bu3ManNAc 500µM 20 




Figure 12 Averaged Growth, Day 1. Over numerous concentrations tested and days utilized, an average cell density per mm2 
was determined for 24 hours (1 day) of growth after initial chemical feed. The corresponding chemical and concentration of the 
treatment are shown above in Table 2. Relative to WT, the 1,3,4-O-Bu3ManNAc performs the best in terms of non-negative 
effects on cell growth. Bu4 was most toxic, with ManNAc and Ac4 displaying worse outcomes than Bu3 but better than Bu4. 
  Figure 12 describes several profound results. Comparatively, concentrations of 1,3,4-O-
BuManNAc (samples 11-20) tended to show relatively similar growth to WT (Sample 1) at 
lower concentrations (sub-125µM). Although treatments 12 and 13 (respectively 20 and 30 µM) 
appear to show an increased growth relative to WT, this lies easily within the range of standard 
deviation for WT and the samples themselves. This is still a positive results, and shows that CHO 
cells treated at those concentrations appear to suffer minimal drawbacks compared to higher 
1,3,4-O-Bu3ManNAc concentrations and similar concentrations of Bu4 and Ac4 treatment.  
  Bu4 particularly threatened cell growth, and was carefully monitored the following days, 
while Ac4 lay between the extremes of 1,3,4-O-Bu3ManNAc and Bu4ManNAc itself showed 






























Figure 13 Averaged Growth, Day 3. An average cell density per mm2 was determined for 72 hours (3 days) of growth after 
initial chemical feed. The corresponding chemical and concentration of the treatment are shown above in Table 2. Relative to 
WT, the 1,3,4-O-Bu3ManNAc performs the best in terms of non-negative effects on cell growth. Bu4 was most toxic, with 
ManNAc and Ac4 displaying worse outcomes than Bu3 but better than Bu4.This is exacerbated even further from Day 1. Sample 
18 (150 µM) was removed due to incomplete data. 
  Day 3 shows a more distinct stratification and diversity of growth volume. While all cells 
except for treatment 11 displayed growth during this time frame, WT, 11, and 12 showed 
dramatic outgrowth of the other treatments, though 3, 16, and 17 showed similar results as well, 
forming a secondary tier below the first three in terms of overall cell growth. Bu4 continued to 
show the most negative effects on growth, and Ac4 was solidly beaten by the Bu3 variant.  
Given that minimization of growth inhibition is one facet of the study in its entirety, 3, 16, and 
17 could remain competitive, or even be more desirable than WT, 11, and 12 if the overall yield 

































Figure 14 Averaged Growth, Day 5. An average cell density per mm2 was determined for 120 hours (5 days) of growth after 
initial chemical feed. The corresponding chemical and concentration of the treatment are shown above in Table 2. Trends from 
Days 1 and 3 are improved further, with the aberrant results of 14-17 departing from the expected trend of a downward or 
constant decrease from sample 12.  
  By Day 5, the growth experiment has more or less shown the expected trend. Base 
ManNAc, Bu4, and the current Ac4 standard have all dramatically fallen off as compared to WT 
and all but the highest two Bu4 concentrations (19, 20). 14 and 15 prove to be aberrations as 
compared to the growth of 12, 13, 16, and 17. Being between 16 and 13, it could be inferred that 
they would show slight decreases from 13, or comparable values to 16, at the very least. Yet this 
was not the case. Possible errors in formulation, or outliers in the creation of the graph could lead 
to this strange results, but “Goldilocks” effects on metabolism have been noted in other cellular 
treatments as well. The standard deviations calculated show a range at which the two could 
overlap, but the lack of accuracy is a cause for further investigation.  
  Figure 15 shows the comprehensive effects of the overall growth from day to day, simply 































Figure 15 Aggregate Growth. A) This figure displays the compiled data from previous, showing net magnitude of growth. The 
1,3,4-O-Bu3ManNAc cluster (12-20) readily outperforms the other clusters, save for wild type. Provided the chemical yields 
similar protein per cell mass yield and SA content, it could prove a boon for large scale cultures. B) Comparatively shows the 
spread and progression of growth over time. 
  Clear competitors for SA yield optimization have begun to emerge based on the growth 
study, namely WT, 3, and the broad collection of Bu3’s from 12-17. However, to avoid missing 
out on a potential high-yield of sialyated protein per cell mass, Ac4 and Bu4 were to be used at 





















































b. Spread Growth Comparison
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  Explanations for these effects are numerous. While analog behavior has been theorized 
previously, it bears reiterating that Bu4 is likely too hydrophobic to properly cross the cell 
membrane, and likely merely contributes to intercellular toxicity than upregulated SA yield. 
Ac4ManNAc’s toxic effects are noted prior in the background.   
2.4.2 Cross-Analog Comparison of Protein Yield 
Protein yield was determined from a uniform volume of cell lysate distributed in 
duplicate in a 96 well plate, and evaluated on a per plate basis using 9 BCA standards to 
establish fluorescence to µg/µl ratio. Samples of interest were narrowed down to WT, and µM 
concentrations of: 1000 ManNAc; 50 Bu4ManNAc; 50, 100, 250 Ac4ManNAc; and 30, 50, 100, 
and 250 1,3,4-O-Bu3ManNAc, based on parameters described in the growth curve. Some were 
selected for their cell growth yield, while others were chosen merely to retain a useful 
comparison. Figure 16 on the following page shows the results of the first day’s protein yield.  
Chemical  Concentration Label 
None  Null 1 
ManNAc 1000µM 2 
Bu4ManNAc 50µM 3 
Ac4ManNAc 50µM 4 
Ac4ManNAc 100µM 5 
Ac4ManNAc 250µM 6 
1,3,4-O-Bu3ManNAc 30µM 7 
1,3,4-O-Bu3ManNAc 50µM 8 
1,3,4-O-Bu3ManNAc 100µM 9 
1,3,4-O-Bu3ManNAc 250µM 10 




Figure 16 Protein Yield for Select Samples, Day 1. From the range of growth effects in figures 12-15, select concentrations 
were used to determine a protein yield, shown above. Corresponding labels and chemical/concentration data are defined in Table 
3. As shown, the lower concentrations of chemicals in general lead to higher protein yield, and the Bu3 cluster demonstrates 
superior performance.  
  While the goal of these experiments remains to maximize SA yield, paying adequate 
attention to protein output from a treatment method is also vital to note for the purposes of bulk-
scale production of biotherapeutics. Even in the event of highly sialyated proteins, the expense 
necessary to cultivate a cell culture with low cellular or protein yield could prove to be a failed 
investment.  
  Day 1 demonstrates that Ac4ManNAc and Bu4ManNAc appear to express lower cellular 
protein relative to wild type, while low concentrations of 1,3,4-O-Bu3ManNAc appear to 
increase it, or at the very least not encourage lower protein expression. A possible explanation 
for this is that chemicals such as sodium butyrate are known to influence increased protein 
expression [51]. In the process of glycomic processing, the admission of Bu groups into the cell 
may be facilitating this mechanism.  
  Of course, there are other, simpler issues which could confound this result inherent in the 






















Protein Yield/Line Day 1
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arise per 96-well plate can be extremely variable. Another issue may simply be lower cell 
volume per lysate, leading to a correlational decrease in overall protein availability.  
  To rectify this simple confound, Figure 17 was constructed. Figure 17 displays the 
protein yield from Figure 16, above, scaled on a per cell density basis assessed in the growth 
experiments. Similar trends as far as the relative magnitude of the various cell line’s protein/cell 
yield indicate that the later samples of 1,3,4-O-Bu3ManNAc  tend towards better protein yield 
than the other analogs. Overall, the protein to cell count remain relatively similar, and lie within 
standard deviations of each other, with the exception of samples 4 and 5. This result is 
reasonable, as apoptotic processes or metabolism diverted towards cell survival may decrease 
protein yield as well as growth in the case of the Bu4 analog. The overall expression being 
similar for the other treatments is reasonable given that SA content, rather than protein 
production, is the target point of optimization. Any benefits in expression, rather than mere 
negation of negatives, are tangential, though merit further study.  
 
Figure 17 Protein Yield per Cell Density for Select Samples, Day 1. This graph frames the protein data on a per cell mass 
basis, allowing for quantitative comparison and removing issues of high cell volume corresponding to high protein values. While 
less apparent than previous figures, this figure nonetheless continues the dominance of 1,3,4-O-Bu3ManNAc, though Samples 2 











































  Figures 18 and 19 continue the analysis of protein and protein/cell data.  
 
Figure 18 Protein Yield for Select Samples, Day 3. The gap between WT and Bu3 samples widens. As could be inferred, the 
lower concentrations of all chemical show a greater preponderance towards higher protein yield than the higher concentrations.  
  Compared to Day 1, the overall protein yield drops off in the same fashion as the cell 
growth does. General protein yield goes up, confirming that the overall protein content increases 
with the volume of cells, which did continue to grow per Figure 15. WT and 1,3,4-O-
BuManNAc continue to be top performers, with lower concentrations of Bu3 yielding the most 
WT-similar results. The lowest concentration, 30 μmol 1,3,4-O-Bu3ManNAc even appears to 
increase protein yield, though this could simply be an aberration rather than a key experimental 
result; all that matters is that Bu3’s performance relative to WT and the other analogs remains 
consistently better. This is particularly true between differing analogs at the same concentrations. 




























Figure 19 Scaled Protein Yield for Select Samples, Day 3. As with the raw protein data, the Bu3 samples show a greater degree 
of protein yield. The Ac4 however, is the more interesting data cluster, as the chemical not only appears to diminish growth in a 
far more pronounced way, but it also seems to reduce protein yield/cell in ways that other analogs seem not to do.   
 
  When scaled again to the growth values, the trend of similarity continues, though the 
overall protein yield for the Bu3 analogs does remain consistent. A possible avenue of inquiry 
between Day 1 and 3 is that Ac4 and ManNAc may be metabolized at a faster rate than 1,3,4-O-
Bu3ManNAc. A factor that is interesting to note is that while the yield/cell decreases across the 
board from Day 1, the decrease is most pronounced for ones which were previously high 











































Figure 20 Protein Yield for Select Samples, Day 5. Sample 8 (50μM 1,3,4-O-Bu3ManNAc) continues its strange dip relative to 
its neighboring concentrations. Other than this, Bu3 has a far easier time of achieving desired protein yields proportional to cell 
mass than its competitors.  
  Compared to Day 3, which correlated to an overall increase in protein and likely cell 
mass, the protein found on Day 5 was diminished dramatically in all but treatments 1, 7, and 9. 
The fact that 8 doesn’t follow this trend, or that 7 rather than 8 does, is unusual and bears further 
investigation, though the overall trend and investigation remain as expected. Day 5’s 
experimental results reduce the need to conduct additional days of study, as divergence between 

























Figure 21 Scaled Protein Yield for Select Samples, Day 5. The overall trend here narrows, with a pronounced spike in 
protein/cell mass of sample 4 (50μM Ac4). While it could be expected, as a whole, that when scaled to their cell masses, the 
average protein yield would be similar across the board, non-Bu3 variants appear nonetheless diminished in their ability to 
produce expected protein, perhaps due to increased emphasis on cell survival.   
  The protein per cell yield for Day 5 raises many interesting questions. While the 
relationship between the magnitude of the columns is similar in shape to Figure 20, treatment 4 
shows a dramatic departure from the general shape of Figure 20. Another point of interest is the 
large, continued drop in ratio. Where treatment 1 (Wild Type) showed a decrease from 10 
μg/ml/(cell density) to 6 μg/ml/(cell density) from Day 1 to Day 3 in Figures 17 and 19, the 
change of about 6 to under 3 marks a similar, higher decrease. Overall protein yield per cell 
volume seems to be decreasing over time, even as cell volume increases, irrespective of 
treatment method. This could arise from cell toxicity from long term exposure, or could be from 










































Figure 22 Aggregate Protein Yield. When taken collectively, the overall yield of protein swings heavily in favor of the Bu3 
cluster (7-10), while the Ac4, Bu4, and even ManNAc show dramatically lower results.  
  Figure 22 (above) shows the aggregate of protein collected over the course of the study, 
while Figure 23 (below) displays the aggregate of protein scaled to cell density.  
 
Figure 23 Scaled Average Protein Yield. As compared to Figure 21, this figure provides a far more uniform distribution of 
protein per cell mass, as might be expected. The Bu3 outliers are still within WT’s standard deviation, and though they do give a 
strong performance, this graph merely exposes Ac4’s negative effect on protein yield rather than essentially improving the 
content within Bu3. 
  In summary, Bu3 continues to compete on-par with WT for overall protein yield and cell 








































































severe drawbacks for the purpose of developing increased SA yield. Comparatively, the Bu3 
performs at a minimum of slightly over 3 (μg/ml)/(cell/mm2) at its lowest value, while the only 
competitor is the 50 μM Ac4 feed. Provided Bu3 can show similar sialic acid content, the 
improved protein yield should encourage usage of the 1,3,4-O-Bu3ManNAc analog over the Ac4 
for large scale processes.  
2.4.3 1,3,4-O-Bu3ManNAc Protein Yield 
The previous section aims to examine the effects of the analogs in comparison to each 
other. This section is a brief investigation into trends within concentrations of 1,3,4-O-
Bu3ManNAc.  
Concentration (1,3,4-O-Bu3ManNAc Label 
o µM/Wild Type 1 
20 µM 2 
30 µM 3 
50 µM 4 
75 µM 5 
100 µM 6 
125 µM 7 
250 µM 8 
500 µM 9 




Figure 24 Day 1 Protein Yield for 1,3,4-O-Bu3ManNAc. Unlike the previous figures, which were designed to showcase a 
comparison across chemical types and concentrations, this protein yield narrows its view to only concentrations of Bu3. This 
shows a downward trend, as might be expected.  
Figures 24, 25, and 26 show the yields of concentrations of 1,3,4-O-Bu3ManNAc in order 
of increasing concentration. Between Days 1 and 3, Bu3 proves consistent, showing and overall 
and generally proportional increase in protein yield across the concentrations, and also shows a 


























Figure 25 Day 3 Protein Yield for 1,3,4-O-Bu3ManNAc. As with figure 24, the downward trend with increasing concentration 
is simply noted.  
Between Day 3 and 5, this downward trend remains semi-apparent, but owing to the 
unexpected result of the 100 and 125 μM concentrations of 1,3,4-O-Bu3ManNAc (previously 






























Figure 26 Day 5 Protein Yield for 1,3,4-O-Bu3ManNAc. While a downward trend is relatively obvious from the first and last 
data points, the middle create an interesting conundrum, addressed as the odd results of the concentrations of treatment 6 and 7 
listed in the growth curve of Figures 12-15 as samples 15 and 16.  
  While a simple result, it is not trivial to acknowledge that increasing concentrations of 
1,3,4-O-Bu3ManNAc does incur several risks associated with the other analogues.  
2.4.4 Lectin Blot 
  Using the BCA technique described previously, uniform protein volumes were seeded 
into an SDS-Page gel, separated, and transferred into a PVDF membrane. They were then 
preblocked, treated with a primary antibody (Lectin I) for SA, and a secondary antibody for the 
primary (Streptradivin). The results of these lectin blots, which display relative SA content for a 
uniform volume of protein, are shown below. Relative darkness indicates higher presence of 


























Figure 27 Lectin Blot, Day 1a. As shown above, the darker bands represent sialic acid content. This in turn can be compared to 
the WT band. Because this is simply a cursory, rather than quantitative look, only the clusters are labeled. Within the rightmost 
(1,3,4-O-Bu3ManNAc) band, concentration of the analog fed decreases, showing lighter bands at lower concentrations. As a 
whole, Ac4 and Bu3 showed significant increases on SA content.  
  Figure 27 shows an initial lectin blot performed on the first day’s samples. As theorized, 
the analogs used increase overall sialic acid content, relative to WT, except for Bu4. Although 
each band indicates a different concentration of analog used, this blot simply establishes a 
positive effect on SA content compared to wild type when using either 1,3,4-O-BuManNAc or 
Ac4ManNAc. The band to the far left, which is darkest, is a ladder rather than sample. As this 





Figure 28 Lectin Blot, Day 1b. Here bands are labeled according to the analog fed. Although somewhat blurry at the lower end 
of the band, all non Bu4 bands show significantly higher SA content than WT, particularly the 250μM and Bu3 bands.  
  Figure 28 displays a similar trend to the blot above, and is also a sample of Day 1. The 
far right lane is difficult to visualize, and has not been labeled due to a lack of useful data from 
the distortion. However, in the remaining lanes, 50μmol and 100μmol 1,3,4-O-Bu3ManNAc 
show similar darkness to the prevailing 100 and 250μmol Ac4ManNAc. Bu4 continues to 
underperform, while WT is not significantly darker than the analogs.  
 
Figure 29 Lectin Blot, Day 3 The labeled bands, though obscure, show the difference in Bu3, high-feed Ac4 and other analogs 
added in over Day 3. Where Day 1 (Figures 27 and 28) are relatively similar across the various chemicals and concentrations, the 
difference becomes more stratified as time goes on.  
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  Day 3 marks the transition point in both protein yield and protein yield per cell growth. 
This blot is included to show that lectin blot assays were done on the SA content for the Day 3 
samples. However, due to numerous logistical issues, Day 3 consistently failed to provide any 
other useful information other than SA was present in various bands. Notably, the bands marked 
for 1,3,4-O-Bu3ManNAc showed the darkest overall presence relative to the illusiveness of the 
other bands.  
 
Figure 30, Day 5a. This blot shows an analysis of Day 5, and shows particularly dark bands at the maximum (250μM) feed level. 
Other bands show modest increases in darkness relative to the high feed. Bu3’s cluster is consistently dark, while Ac4 shows 
mixed results, with very little display in 50μM feed volumes. This blot also shows a 1000μM feed, and while very dark, is not 
substantially more competitive than 250μM Ac4 or 100/250μM Bu3. 
  Figure 30’s blot shows the results of a Day 5 investigation. Relative to the similar 
concentrations of Ac4, Bu3 shows darker bands and a higher presence of SA throughout the 




Figure 31 Lectin Blot, Day 5b. This blot is the most characterized and most distinctly shows the difference between WT, Bu4, 
and Ac4 and Bu4 variants. Bu3 shows a uniformly high SA content, and shows a competitive comparison of the 100Bu3 and 
250Ac4 bands, indicating a higher SA per concentration value when feeding Bu3.  
  Compared to the previous Day 5 sample, this blot evaluates each lane independently. 
Lanes were chosen to maximize contrast and capitalize on previous lectin blots in hopes of 
creating a blot which more clearly represents the qualitative data cleaned from previous 
investigative studies. In the blow, Bu4 and WT show mild differences in SA content, while 50Ac 
has a darker band, virtually indistinguishable, however, from the 100Ac band. By contrast, 
250Ac4 is very dark, showing a notable increase in SA content. But the comparison with the 
1,3,4-O-Bu3ManNAc samples is illuminating.  
  While the 250 and 100μmol bands of the Bu3 studies are virtually indistinguishable, they 
show a marked increase in SA content over the 50; furthermore, they show comparable increase 
in SA to the 250Ac4 band, with the 50 and 100 Bu3 bands obviously outperforming the 50 and 
100 Ac4 bands. The 50Bu3 band outperforms, quite visibly, all bands except for the 250Ac4 
band. The increased concentrations of 100 and 250Bu3 also visibly show darker bands than the 
250Ac4.   
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  Taken as a whole, Bu3 seems to give greater SA content/protein than Ac4. When taken 
into consideration with the previous means in which Bu3 had better protein and cell mass yields, 
1,3,4-O-Bu3ManNAc is a clear winner in the comparison between the analogs.  
  A more direct comparison using an excision from Figure 29 was developed to provide a 
greater contrast, showing that SA increased between the 50, 100, and 250 μmol samples, shown 
in Figure 32 below.  
 
Figure 32 Lectin Blot Day 3 1,3,4-O-Bu3ManNAc direct comparison. Removal of the other lanes allows for precise 
visualization of the increasing SA content characteristic of increased concentration of Bu4. As shown, the darker bands correlate 




Chapter 3: Conclusions 
  All analogs, with the dubious exception of the Bu4 analog, were shown to increase SA 
content relative to wild type. Comparatively, 1,3,4-O-Bu3ManNAc was less toxic on the effects 
of cell growth over the course of the days studied, particular compared to the current Ac4 
standard. This trend continued to the overall protein yield. While there were some oddities in the 
values of 75 and 100 μmol 1,3,4-O-Bu3ManNAc. For uniform protein concentrations, lectin-
blotted 1,3,4-O-Bu3ManNAc showed a higher increase in SA content than  comparable Ac4, and 
showed a steady increase In SA content with increasing 1,3,4-O-Bu3ManNAc concentration. 
Furthermore, it showed a greater degree of increase in SA content when compared to higher 
concentrations of Ac4ManNAc, in particular the comparison of 100(u)mol 1,3,4-O-Bu3ManNAc 
as compared to the 250 μmol Ac4ManNAc. 
  Overall, 1,3,4-O-Bu3ManNAc has qualitatively shown to be an equivalent, if not 
superior, alternative to increasing sialic acid content through a chemical rather than genetically 




Chapter 4: Further Research 
4.1 HPLC 
High performance liquid chromatography (HPLC) can be used in order to separate a 
mixture based on numerous characteristics. Reverse phase HPLC allows for high specificity of 
analysis.  
4.1.1 Nucleotide Sugars 
  Nucleotide sugars are metabolites that often form intermediates in the formation of 
glycan structures (a total of twelve for uridine, cytosine, guanine, and adenine, each with a 
mono-, di-, and tri- phosphate). Specific focus on CMP-Neu5Ac could be beneficial for its 
membrane permeability and SA throughput.  
  Methods have been detailed for various solvents and methods for the extraction and 
quantification of nucleotide sugars. Further development of metabolic models could benefit from 
the determination of the effects on various metabolic pathways and the change in NT sugar 
composition on a per-analog exposure basis.  
  By monitoring these effects, it would help in the development of further in silico 
modeling of sialic acid flux pathways.  
4.1.2 Glycan Depletion  
  PNGase F (New England BioLabs, Ipswich, MA) is a common enzyme used to cleave N-
glycans from proteins in order to study numerous traits of de-glycosylated proteins. One other 
benefit involves the separation of the actual glycans.  
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  After cleaving the glycans and separating them out from the whole cell lysate, using 
HPLC to determine SA peaks could come in handy for quantitative analysis of overall SA yield 
within the lysate content.  
4.2 Specific Proteins 
  Using the metabolic model proposed above, further investigation into cell line parameters 
could be further evaluated for particular proteins of interest. Although this study encompassed 
broadly the overall effects of SA regulation via a whole-cell lysate analysis, the ultimate goal of 
most cell culture work is to increase industrial ability to produce high-quality glycoproteins. 
Applying these methods to a specific therapeutic could yield quite useful data.  
4.3 Other Analogs 
  Although only ManNAc and three other analogs (Ac4, Bu4, and 1,3,4-O-Bu3ManNAc) 
were tested, there exist a huge variety of chemical modifications which have shown interesting 
properties. The 3,4,6-O-Bu3ManNAc variant shows useful apoptotic properties, and could be 
cultured for in situ or in vitro cancer models and metabolic effectors.  
  Additionally, the usage of azide groups in the core ring structure of the analog could 
show many useful diagnostic traits due to the inherent Az-Az conjugation and the growing 
popularity of click chemistry methods.  
4.4 Combined Approach of Analogs and Genetic Engineering 
  A viable avenue of inquiry could involve the combined approach of the chemical analogs 
co-used with genetically engineered lines already showing increases in terminal sialic acid 
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content. It would be interesting to find out whether or not bioengineered platforms optimized for 
throughput could be further augmented by chemical means.  
 
Figure 33 Variant ManNAc Synthesis Pathway. Bacteria are relatively less complex in their synthesis pathway. Transfection of 
the gene into CHO to examine metabolic throughput might be a viable means of investigation. [22] 
 Various organisms utilize variants of the sialic acid synthesis pathway. Examining these 
variants and testing for throughput or cell line minimization may prove to be of interest.  
4.5 Treatment Phase 
 Cells in this study were treated in the initial growth phase, and examination was stopped 
before exponential phase due to cell death or parity. Testing the effects of the analogs at different 
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